Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

JUPITER II: Double blind randomised comparison of JANUS Tacrolimus-eluting stent with the Tecnic Carbostent

06.09.2005


JUPITER II is an international multi-centre, double blind, randomized clinical trial designed to evaluate the safety and efficacy of JANUS Tacrolimus-eluting Carbostent in the treatment of coronary lesions in “direct stenting” procedures as compared to TECNIC Carbostent. A total of 332 patients were enrolled in 16 European centers and randomized to either JANUS (166 patients) or TECNIC (166 patients). Enrolment was completed on 21 December 2004 and direct stenting was performed in 86.1% of procedures for Tecnic group and in 75.9% of procedures for Janus group. The complete six-month clinical data (160 patients in Tecnic group and 157 patients in Janus group) clearly highlight strong clinical efficacy and safety.



The study reported stent related MACE of 10.6% (17 TLR out of 160 patients) for the control Tecnic group and a more favourable rate of 6.4% (9 TLR and 1 MI out of 157 patients) for Janus group (ns). The 6 month clinical efficacy of Janus stent is expressed by a 46% reduction in TLR in respect to Tecnic stent (TLR of 5.7% with Janus versus 10.6% with Tecnic). The occurrence of MACE in Jupiter II study is mainly related to TLR, the incidence of events such as death, AMI or CABG is negligible.

The Janus stent also exhibits a high level of safety, as demonstrated by 0% stent thrombosis rate (sub-acute and late) in both groups, confirming all previous clinical results with Tecnic and other Carbofilm coated stents.


Analysis of the angiographic follow-up data is almost completed and I will be delighted to present them at TCT in Washington,” commented Dr. Marie-Claude Morice. “The complete six-month clinical results of Jupiter II demonstrate the excellent clinical outcome and safety profile for the JANUS polymer-free drug-eluting stent technology, as demonstrated by the low MACE rate with Janus and a 46% reduction of TLR of versus Tecnic”.

Gina Dellios | alfa
Further information:
http://www.escardio.org/vpo/ESC_congress_information/ConferenceReleases/

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

High-precision magnetic field sensing

05.12.2016 | Power and Electrical Engineering

Construction of practical quantum computers radically simplified

05.12.2016 | Information Technology

NASA's AIM observes early noctilucent ice clouds over Antarctica

05.12.2016 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>